Full results & analysis
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Xinlikang capsule for chemotherapy-induced fatigue in DLBCL
NCT07084662Phase 3
Key facts
- Status
- Recruiting
- Start
- Sep 2025
- Primary completion
- Aug 2028
- Countries
- 1
- Sponsor
- Sun Yat-sen University
- Modality
- Small Molecules
- Drugs
- enalapril
- Conditions
- cancer-related fatigue (CRF)
01
Overview
Phase 3, randomised, double-blind trial of enalapril in cancer-related fatigue (CRF) (2 arms), sponsored by Sun Yat-sen University. Primary endpoint: Functional Assessment of Chronic Illness Therapy - Fatigue Scale at 12 weeks. Started Sep 2025; status: recruiting.
02
Design
2 arms- Study design
- RandomizedDouble-blind
Xinlikang capsules
Xinlikang capsules, 5 capsules each time, 3 times a day
Mimic capsules
Placebo capsules, 5 capsules each time, 3 times a day
03
Endpoints
Primary
Functional Assessment of Chronic Illness Therapy - Fatigue Scale
Secondary
Functional Assessment of Chronic Illness Therapy - Fatigue Scale
Brief Fatigue Inventory
Functional Assessment of Cancer Therapy - Lymphoma
Beyond the preview
Go deeper on NCT07084662.
Full results, competitive context and analysis are in the Gosset platform.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07084662.